By Jeff Rose Zacks cut shares of Histogenics Corp (NASDAQ:HSGX)from a hold rating to a sell rating in a research reportsent to investors on Thursday morning, Market Beatreports. According to Zacks, “Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products